Publications by authors named "A H Gesierich"
Background: Up to now, the optimal duration of immune checkpoint inhibitors (ICI) has not been evaluated in prospective studies. However, current clinical practice requires decisions to be made regarding the duration of ICI in complete responders.
Material And Methods: A survey was sent to 80 DeCOG skin cancer centers to assess how decisions are made on treatment duration of ICI in melanoma after having reached complete response, and staging intervals after ICI discontinuation.
Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous malignancy. Immune checkpoint inhibition (ICI) with PD-(L)1 blockade has significantly improved treatment outcomes in metastatic disease. In patients with primary resistance to PD-(L)1 inhibition, a high overall response rate (ORR) of 50% to later-line ipilimumab plus nivolumab (IPI/NIVO) has been demonstrated.
View Article and Find Full Text PDFArticle Synopsis
- A study conducted from November 2020 to June 2023 assessed the performance of SARS-CoV-2 rapid antigen tests (RDTs) compared to standard RT-qPCR testing among a large group of patients and staff in a hospital setting.
- The analysis of nearly 78,800 paired results revealed that RDTs had a sensitivity of 34.5% and a specificity of 99.6%, with sensitivity decreasing as fewer symptomatic infections occurred over the course of the pandemic.
- The findings suggest that RDTs are still effective for diagnosing COVID-19 in symptomatic patients and could be useful for identifying other respiratory infections in the future, despite their declining sensitivity linked to vaccination and the spread of the Omicron variant
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol
November 2024
Article Synopsis
- - The treatment options for metastatic uveal melanoma (UM) are still limited and the overall prognosis is poor, despite recent advancements; immune checkpoint blockade (ICB) is a common treatment but can cause severe adverse effects.
- - A study involving 194 patients analyzed the relationship between immune-related adverse events (irAE) and survival outcomes, finding that those with severe irAE had better overall survival compared to those without or with mild irAE.
- - The results suggest that certain types of irAE, like irColitis and irHepatitis, may be linked to longer survival, indicating that a lower tolerance to tumor antigens might correlate with a lower tolerance to self-antigens.